Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Article

Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change

Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham III, Michael Weinblatt and Nancy A Shadick
The Journal of Rheumatology June 2019, jrheum.181160; DOI: https://doi.org/10.3899/jrheum.181160
Taysir G Mahmoud
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Huang
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Frits
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Iannaccone
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivian Bykerk
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifton O. Bingham III
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Weinblatt
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy A Shadick
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud{at}bwh.harvard.edu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
Next
Loading

Abstract

Objective Describe strategies used to manage rheumatoid arthritis (RA) flares that contribute to a successful post flare outcome.

Methods Data were collected from the BRASS registry, including clinical and patient reported outcomes, and a survey with a Likert scale assessing post flare symptoms (better, unchanged, or worse). A logistic regression analysis adjusting for age, sex, flare number in the past 6 months, flare pain severity, home management, clinical consultation, and medication change was performed to evaluate factors influencing flare outcome. Clinical trial registration: NCT01793103.

Results Of 503 participants, 185 reported at least one flare that had resolved in the past 6 months, median (IQR) DAS28-CRP3 score 2.1 (1.7, 2.8). Compared with RA symptoms before the flare, 22 (12%) patients felt worse, 125 (68%) were unchanged, and 38 (20%) felt better. To manage flares, 72% of patients used home-based remedies, 23% sought clinical consultation, and 56% made medication change. Of 103 patients who changed medication, 70% did so without seeking clinical advice. Making a medication change [OR 3.48 (1.68, 7.21)] and having lower flare pain [OR 0.83 (0.71, 0.97)] were associated with better flare outcome.

Conclusion Flares occur frequently even in patients with low disease activity. Independent of home-based or clinically guided care, making a medication change and having less severe pain during a flare were associated with better flare outcomes. Of interest, the decision to change medications was frequently made without clinical advice. Future directions might address how best to intervene when patients experience flares and whether patient initiated medication changes have adverse outcomes.

Next
Back to top

In this issue

The Journal of Rheumatology: 53 (3)
The Journal of Rheumatology
Vol. 53, Issue 3
1 Mar 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham , Michael Weinblatt, Nancy A Shadick
The Journal of Rheumatology Jun 2019, jrheum.181160; DOI: 10.3899/jrheum.181160

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham , Michael Weinblatt, Nancy A Shadick
The Journal of Rheumatology Jun 2019, jrheum.181160; DOI: 10.3899/jrheum.181160
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire